Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals received a Buy rating and an $115.00 price target from J.P. Morgan analyst today. The word on The Street in general, suggests...

Mirum Pharmaceuticals (MIRM) Gets a Buy from J.P. Morgan

Mirum Pharmaceuticals ( ($MIRM) ) just unveiled an announcement. On May 15, 2026, Mirum Pharmaceuticals issued $690 million of 0.00% Convertible Se...

Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes

In a report released today, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $154.00. A...

Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright assigned a Buy rating to Mirum Pharmaceuticals, with a price target of $185...

Mirum Pharmaceuticals (MIRM) Gets a Buy from H.C. Wainwright

In a report released today, Lisa Walter from RBC Capital maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $142.00. Accordin...

RBC Capital Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InflaRx (IFRX) and Mirum Pharmaceuticals (MIRM) with...

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)

The latest announcement is out from Mirum Pharmaceuticals ( ($MIRM) ). On May 4, 2026, Mirum Pharmaceuticals reported that its VISTAS Phase 2b tria...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIRM	$99.05	+0.43%	265.74K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIRM	$99.05	+0.4%	265.74K
3
4
5
6

MIRM

MIRM

Get Mirum Pharmaceuticals Inc. Data in Excel

Get Mirum Pharmaceuticals Inc. Data in Excel